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Cancer immunotherapies are increasingly combined with targeted
therapies to improve therapeutic outcomes. We show that combi-
nation of agonistic anti-CD40 with antiangiogenic antibodies target-
ing 2 proangiogenic factors, vascular endothelial growth factor A
(VEGFA) and angiopoietin 2 (Ang2/ANGPT2), induces pleiotropic
immune mechanisms that facilitate tumor rejection in several tumor
models. On the one hand, VEGFA/Ang2 blockade induced regression
of the tumor microvasculature while decreasing the proportion of
nonperfused vessels and reducing leakiness of the remaining vessels.
On the other hand, both anti-VEGFA/Ang2 and anti-CD40 independently
promoted proinflammatory macrophage skewing and increased
dendritic cell activation in the tumor microenvironment, which were
further amplified upon combination of the 2 treatments. Finally,
combined therapy provoked brisk infiltration and intratumoral redis-
tribution of cytotoxic CD8+ T cells in the tumors, which was mainly
driven by Ang2 blockade. Overall, these nonredundant synergistic
mechanisms endowed T cells with improved effector functions that
were conducive to more efficient tumor control, underscoring the
therapeutic potential of antiangiogenic immunotherapy in cancer.
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Reinvigoration of T cell function by PD-1 and/or CTLA-4 immune checkpoint blockade can result in striking clinical
responses in selected cancer types, yet these treatments are ef-
fective only in a minority of cancer patients (1, 2). Agonistic
targeting of CD40 represents an alternative approach for pro-
moting antitumor immunity (3). CD40, a tumor necrosis factor
(TNF)-receptor superfamily member, is primarily expressed on
antigen-presenting cells (APCs), including dendritic cells (DCs), B
cells, macrophages, and monocytes, as well as nonhematopoietic
cells and subsets of cancer cells. Ligation of CD40 with CD40L
(CD154) results in direct activation of APCs, which involves up-
regulation of costimulatory and MHC molecules and production
of proinflammatory cytokines. This is a key step in the generation
of an antitumor immune response, and there is evidence that ago-
nistic CD40 antibodies facilitate rejection of established tumors in
different mouse models of cancer (4, 5). CD40-targeting antibodies
with varying binding affinity are evaluated in clinical trials, including
selicrelumab (RG7876), dacetuzumab, APX 005M, ChiLob 7/4, and
lucatumumab (3, 6). While toxicity appears manageable and dura-
ble anticancer responses were observed, clinical activity of single-
agent CD40 antibodies appears to be rather modest, with response
rates of <20% in patients (6). Clinical efforts are currently directed
at exploring combinations of anti-CD40 with chemotherapy, PD-1/
PD-L1 blocking antibodies (e.g., NCT02304393, NCT03502330,
NCT03123783, and NCT02706353), or antiangiogenic antibodies
bevacizumab (Avastin; a clinically approved antivascular endo-
thelial growth factor A [anti-VEGFA] antibody) and vanucizumab
(an anti-VEGFA/Ang2 bispecific antibody) (NCT02665416).
Angiogenesis contributes to tumor growth and progression by
inducing and maintaining an acidic/hypoxic and immunosuppres-
sive environment (7, 8). The tumor frequently harbors dysfunc-
tional blood vessels, which limit T cell trafficking (7). Furthermore,
several proangiogenic growth factors, primarily VEGFA, limit DC
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maturation and promote the accumulation of immunosuppressive
immature myeloid cells in tumors (9–11). Blocking proangiogenic
growth factors may, therefore, not only inhibit angiogenesis but
also relieve immunosuppression in tumors. Several antiangiogenic
therapies that block VEGFA signaling are tested both preclinically
and clinically. Yet, anti-VEGFA therapies combined with
standard-of-care treatments increase progression-free survival by
only 3 to 6 mo with minor, if any, improvement of overall survival
rates, depending on the cancer type (12). In glioblastoma patients
and various mouse cancer models, resistance to anti-VEGFA
therapy may be associated with the induction of the proangio-
genic factor angiopoietin 2 (Ang2/ANGPT2), a ligand of the
TIE2/TEK receptor (13–15). In various tumor models, Ang2/
Tie2 inhibition reduces tumor growth in the presence of active
VEGFR signaling; nevertheless, greater inhibitory effects on an-
giogenesis and tumor growth are observed with combined block-
ade of Ang2 and VEGFA (15–22). Additionally, Ang2 blockade
induces blood vessel normalization, blocks metastasis, and pro-
motes a proinflammatory tumor microenvironment (9, 17, 20, 23–
25). Ang2 inhibition, with or without concurrent VEGFA in-
hibition, is being evaluated in clinical trials in combination with
chemotherapy and other anticancer agents (14, 26).
Preclinically, both DC101, an anti-VEGFR2 antibody, and
A2V, an anti-VEGFA/Ang2 bispecific antibody, have been shown
to increase the efficacy of anti–PD-1/PD-L1 immunotherapy by
increasing T cell trafficking in tumors (22, 27). Several clinical
studies (NCT03439891, NCT03277924, NCT03616691, and
NCT03074513) are evaluating the efficacy of antiangiogenic
therapy in combination with immune checkpoint blockade (1, 2,
26, 28, 29). Anti-CD40 immunotherapy (3–6, 30, 31) might rep-
resent a complementary approach to immune checkpoint inhibi-
tors for combination with angiogenesis inhibitors (32). In this
study, we show that combination of agonistic CD40 antibodies
with dual VEGFA/Ang2 blockade enhances antitumor responses
in mouse cancer models through synergistic gene regulation and
the induction of an immune permissive tumor microenvironment
characterized by proinflammatory (M1-like) macrophage activa-
tion, vascular normalization, and improved infiltration and spatial
localization of effector T cells.
Results
Combination of Anti-VEGFA, Anti-Ang2, and Agonistic Anti-CD40
Antibodies Enables Tumor Rejection in Syngeneic Tumor Models.
We examined tumor responses to anti-VEGFA, anti-Ang2, and
agonistic anti-CD40 antibodies in various mouse cancer models
(for details on cancer models, refer to Materials and Methods and
Dataset S1). We utilized the following antibodies as antiangiogenic
agents: murinized anti-Ang2 (clone LC06) (22), murinized anti-
VEGFA (clone B20.4.1) (33), and a combination of anti-Ang2
and anti-VEGFA or a murinized bispecific antibody targeting
the 2 proangiogenic factors (A2V) (19, 22, 24). In order to ac-
tivate CD40, we used 2 anti-CD40 antibodies, clone 1C10 (mu-
rine immunoglobulin 1 [IgG1]) and clone FGK45 (rat IgG2a),
which are both dependent on Fc receptor cross-linking and
recognize the same CD40 epitope (34). Control mice received
irrelevant IgGs or histidine buffer. Treatments and dosage reg-
imens are described in detail in Dataset S1.
Single-agent treatments had modest antitumor activity com-
pared to control IgGs in the MC38 colorectal adenocarcinoma
model (Fig. 1A). Combination of Ang2 and VEGFA inhibition
had additive antitumoral effects, consistent with previous studies
(22). Whereas anti-CD40 only had modest inhibitory effects in
combination with anti-VEGFA (1/17 tumor-free mice), it in-
duced stabilization of tumors in a larger proportion of the mice
when combined with either anti-Ang2 (6/17 tumor-free mice) or
anti-VEGFA/Ang2 (9/17 tumor-free mice); notably, the combi-
nation of the 3 antibodies provided the most pronounced survival
benefits (Fig. 1B). When we analyzed MC38 tumors on-therapy
in an independent experiment, we found greater intratumoral
necrosis after anti-Ang2/CD40 or anti- VEGFA/Ang2/CD40
treatment, emphasizing the critical contribution of Ang2 blockade
to the therapeutic response (Fig. 1 C and D). Of note is that anti-
CD40 monotherapy or its combination with VEGFA/Ang2 did not
cause liver damage, cell dropout, or fibrosis, although a mild
mononuclear infiltrate, strictly confined to portal tracts, was ob-
served in both treatment groups (SI Appendix, Fig. S1A).
Analysis of other tumor models revealed additive antitumoral
effects of anti-VEGFA/Ang2 plus anti-CD40. Even in established
orthotopic MMTV-PyMT (mouse mammary tumor virus-polyoma
virus middle-T antigen) mammary tumors, which are insensitive to
anti-CD40 treatment, combined CD40 activation and VEGFA/
Ang2 blockade had superior antitumoral activity, resulting in tu-
mor growth stabilization in 3 out of 10 mice (SI Appendix, Fig. S1
B and C). We obtained similar results in the CT26 colon carci-
noma and E0771 mammary tumor models (SI Appendix, Fig. S1 E
and F). The combined treatment improved tumor control also
in chicken ovalbumin (OVA)-expressing B16 melanomas (B16-
OVA), which are sensitive to both VEGFA/Ang2 inhibition and
CD40 activation (SI Appendix, Fig. S1D). Together, these results
indicate that combining anti-VEGFA/Ang2 with agonistic anti-
CD40 antibodies produces robust survival benefits, including tu-
mor rejection, in different mouse models of cancer.
Dual VEGFA/Ang2 Blockade Reprograms Tumor-Associated Blood
Vessels. We examined microvessel density (Fig. 2 A–D), leaki-
ness (Fig. 2E), and perfusion (Fig. 2F) in MC38, MMTV-PyMT,
and B16-OVA tumors. The relative abundance of CD31+ blood
vessels was reduced by both anti-VEGFA/Ang2 and anti-VEGFA/
Ang2/CD40 compared to control IgGs in the 3 models tested (Fig.
2 A–D). Anti-CD40 monotherapy did not alter microvessel density
compared to control tumors.
Increased leakiness and reduced perfusion of immature blood
vessels may impair intratumoral drug delivery and immune cell ex-
travasation (11). We performed intravenous (i.v.) injection of fluo-
rescein isothiocyanate (FITC)-dextran (70 kDa) or FITC-lectin to
visualize leaky and nonperfused (nonfunctional) blood vessels, re-
spectively, in MC38 tumors (Fig. 2 E and F). The fraction of non-
functional CD31+ vessels was significantly reduced in the anti-
VEGFA/Ang2 and anti-VEGFA/Ang2/CD40 treatment groups, sug-
gesting normalization and/or increased maturation of the remaining
blood vessels; however, we did not observe additive effects of anti-
CD40. We also performed dual NG2 and CD31 immunostaining to
examine pericyte coverage, which is indicative of vascular maturation
(11). We found that anti-Ang2/CD40 increased pericyte coverage of
tumor blood vessels. This effect was partly limited by the addition of
anti-VEGFA (Fig. 2G) and could be explained by the antiangiogenic
effect of VEGFA blockade, which may contribute to decreasing
maturation while improving functionality of the blood vessels
(22, 24). Therefore, dual VEGFA and Ang2 inhibition induces
both vascular pruning and normalization of residual blood ves-
sels in different mouse tumor models.
Anti-VEGFA/Ang2/CD40 Treatment Promotes Myeloid Cell Skewing in
Tumors. Anti-CD40 therapies target myeloid cell populations in
tumors, leading to their activation and maturation (35–37). Dual
VEGFA and Ang2 blockade was shown to promote myeloid cell
activation in tumors, including M1-like tumor-associated macro-
phage (TAM) skewing and improved antigen presentation by DCs
(22, 24). We then asked whether anti-CD40 plus VEGFA/
Ang2 could cooperatively foster immunostimulatory myeloid cell
activation in tumors. We observed that anti-CD40 either alone or in
combination with anti-VEGFA/Ang2 markedly reduced the fre-
quency of CD11b+Ly6C−Ly6G–F480+ macrophages (TAMs) in the
leukocyte infiltrate of MC38 tumors (Fig. 3A). However, the triple
combination significantly decreased the proportion of CD206hi
CD11clow M2-like TAMs and consequently increased the M1/M2
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Fig. 1. Therapeutic efficacy of Ang2/VEGFA blockade in combination with agonistic CD40 antibodies. (A) Tumor volume and (B) Kaplan−Meier survival
plot of MC38 tumors inoculated s.c. in C57BL/6 mice. Mice were treated as indicated. Anti-CD40 (1C10) or control muIgG (both at 5 mg/kg) were ad-
ministered i.p. on days 18, 20, 23, and 25, whereas anti-VEGFA and anti-Ang2 (both at 10 mg/kg) were administered i.p. on days 18 and 23 postcell
inoculation. Pooled data of 3 independent experiments are shown. The number of tumor-free mice out of the total number of mice, assessed at day
100 posttumor challenge, is indicated in each graph in A. (C ) Relative necrotic area in MC38 tumors treated as indicated, measured in the largest tumor
section. Each dot indicates one tumor. Data indicate mean values ± SEM. Statistical analyses by 1-way ANOVA with Tukey’s correction for multiple
comparisons. (D) Representative images of tumor sections stained with hematoxylin/eosin. (Scale bar, 1,000 μm.) The number of mice employed in each
experiment is reported in Dataset S2.
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TAM ratio (M1-like TAMs: CD206lowCD11chi), compared to the
other treatments. In the B16-OVAmodel, only the combined anti-
VEGFA/Ang2/CD40 treatment decreased TAMs (Fig. 3B).
However, both anti-CD40 and VEGFA/Ang2 blockade decreased
M2-like TAMs, and the magnitude of the effect was greater after
the combined treatment. We observed similar effects on TAMs in
the MMTV-PyMT model, in which only the combined treatment
detectably decreased TAMs (Fig. 3C).
Intratumoral APCs, identified as CD11b+Ly6G−Ly6C−F4/
80−CD11chi cells, displayed enhanced expression of the activation and
maturation markers CD86 and MHC-II after anti-VEGFA/Ang2/
CD40 therapy in the B16-OVA model (Fig. 3 D, Left and Middle).
In the MC38-OVA model, higher MHC-II expression was observed
on DCs of tumor-draining lymph node (TDLN) of mice treated
with combination therapy (SI Appendix, Fig. S2A). Accordingly, the
density of SIINFEKL/H-2Kb MHC-I complexes on B16-OVA
tumor infiltrating APCs was higher in the anti-VEGFA/Ang2/
CD40 treatment group (Fig. 3 D, Right) and on APCs of TDLN of
MC38-OVA tumor-bearing mice (SI Appendix, Fig. S2B), sug-
gesting improved processing of the surrogate tumor antigen OVA
by APCs through the antigen cross-presentation pathway. In
agreement with previous studies (22, 24, 38), both CD40 activation
and VEGFA/Ang2 blockade had stimulatory effects on APCs, al-
though the magnitude of the effect in monotherapy was inferior to
that in the combination group. Overall, these results indicate
marked stimulatory activation of the innate immune cell com-
partment of tumors by combined targeting of CD40 and VEGFA/
Ang2.
Combination of Anti-VEGFA/Ang2 and Anti-CD40 Synergistically Induces
Transcriptional Changes in Macrophages, T Cells, and Endothelial Cells.
In order to identify molecular pathways and cell types directly
regulated by antiangiogenic immunotherapy, we performed RNA
sequencing (RNA-seq) analysis of distinct immune cell types (F4/
80+ TAMs, CD4+, and CD8+ T cells) and CD31+ endothelial cells
(ECs) isolated from MMTV-PyMT tumors 5 d after treatment, as
described previously (22). In clear contrast to the monotherapies,
several unique genes were differentially regulated in the anti-
VEGFA/Ang2/CD40 combination group, especially in CD8+
T cells, macrophages, and CD31+ cells (Fig. 4 A and B and Datasets
S3 and S4). When assessed across all treatment groups and cell
types, the differential regulation was found to be cell type-specific
and unique to the combination group (SI Appendix, Fig. S3A).
These unique transcriptomic changes highlight the synergistic ac-
tivity of anti-CD40 and anti-VEGFA/Ang2 treatment combination.
Pathway analysis in sorted TAMs revealed that anti-VEGFA/
Ang2/CD40, compared to anti-CD40 monotherapy, enhanced
pathways in the biofunctional groups of chemoattraction and re-
cruitment of phagocytes/leukocytes, and activation of lymphocytes
(Fig. 4C). Among the genes activated by the combined treatment in
TAMs were Cd80, Il12b, and Ccl19 (SI Appendix, Fig. S3 B and C).
The upstream regulators of proinflammatory pathways, namely
Tlr4, Tnf, Ifng, and Il1b, were overrepresented in both TAMs and
ECs after combined anti-VEGFA/Ang2/CD40 treatment (Fig. 4D).
Fig. 2. Antiangiogenic and vascular-modulatory effects of Ang2/VEGFA blockade in combination with agonist CD40 antibodies. (A) Representative images of
CD31 immunostaining (red) and DAPI nuclear staining (blue) of MC38 tumors treated with the indicated antibodies. (Scale bar, 100 μm.) (B–D) Relative CD31+
area in (B) MC38 and (C) MMTV-PyMT and (D) flow cytometry analysis of CD31+ cells in B16-OVA tumors. Each data point indicates one tumor per mouse and
represents an average of at least 4 images per tumor (B and C). (E) Analysis (Left) and representative image (Right) of CD31+ vessels in MC38 tumors treated as
indicated. Vascular leakage was identified by FITC-dextran in the abluminal compartment of CD31+ blood vessels (arrowhead). Each data point represents one
image; at least 3 representative images were analyzed per tumor. (Scale bar, 100 μm.) (F) Analysis (Left) and representative image (Right) of CD31+ vessels in
MC38 tumors treated as indicated. Nonperfused CD31+ vessels were identified by absence of FITC-lectin staining (asterisks). Each data point represents one
image; at least 3 representative images were analyzed per tumor. (Scale bar, 100 μm.) (G) Relative proportion of NG2+ pericyte-covered blood vessels in
MC38 tumors treated as indicated. Each dot indicates one tumor. Data indicate mean values ± SEM. Statistical analyses by 1-way ANOVA with Tukey’s
correction for multiple comparisons, unless otherwise indicated in Dataset S2. The number of mice employed in each experiment is reported in Dataset S2.
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Anti-CD40 appeared to regulate those genes in TAMs, whereas
their modulation in ECs was regulated by anti-VEGFA/Ang2, as
reported previously (22) (Fig. 4D). Nevertheless, the combined
treatment led to enhanced activation of the aforementioned
proinflammatory regulators, as well as down-regulation of sup-
pressor of cytokine signaling 1 (Socs1), a negative regulator of
inflammation (39) in both TAMs and ECs (Fig. 4D).
We further investigated the expression of the proinflammatory,
T cell-recruiting and activating cytokines Il12, Il1b, Cxcl9, and
Cxcl10 in bulk MMTV-PyMT tumors by qPCR (Fig. 4E). Each
gene displayed the highest induction after anti-VEGFA/Ang2/
CD40 treatment, whereas anti-CD40 monotherapy and dual
VEGFA/Ang2 blockade had modest, if any, effects. Collectively,
these data indicate that anti-CD40−based antiangiogenic immuno-
therapy combination promotes the generation of a proinflammatory
and immune-stimulatory tumor microenvironment, which may un-
derlie the synergistic antitumoral effects observed across different
tumor types.
Anti-VEGFA/Ang2/CD40 Improves CD8+ T Cell Infiltration and Promotes
Their Spatial Redistribution in Tumors.Anti-CD40 distinctly increased
CD8+ T cell infiltration in both MC38 and B16-OVA tumor models
with little, if any, additive effects after combination with anti-
VEGFA/Ang2 blocking antibodies (Fig. 5 A and B). Total CD45+
hematopoietic cell infiltration remained unchanged across treat-
ment and control tumors (SI Appendix, Fig. S4A). Total CD4+ T
cells remained relatively unchanged in MC38 tumors and in-
creased in both anti-CD40 and anti-VEGFA/Ang2/CD40−treated
B16-OVA tumors (SI Appendix, Fig. S4 B and C). However, CD4+
FoxP3+ regulatory T cells (Tregs) decreased in both anti-CD40
and anti-VEGFA/Ang2/CD40 treatment groups in MC38 tumors
(Fig. 5 C, Left), which contributed to increasing the CD8+/Treg
cell ratio in the treatment groups containing anti-CD40 antibodies
(Fig. 5 C, Right). Accordingly, Treg gene signatures were markedly
down-regulated by anti-VEGFA/Ang2/CD40 combination in
CD4+ T cells isolated from MMTV-PyMT tumors (SI Appendix,
Fig. S4D).
Although anti-CD40 monotherapy promoted CD8+ T cell in-
filtration in the tumors, only its combination with anti-VEGFA/
Ang2 induced tumor rejection (Fig. 1 A and B). We speculated
that vascular modulation by VEGFA/Ang2 blockade (Fig. 2)
could improve the trafficking of tumor-reactive T cells. We,
therefore, examined homing of OVA-specific CD8+ T cells (OT-I
cells) to MC38-OVA tumors after adoptive transfer into tumor-
bearing mice. We observed increased frequency of OT-I cells in
MC38-OVA tumors (Fig. 5D) but not in TDLN and spleen of
mice that received the combination therapy.
We further analyzed the spatial distribution of CD8+ T cells in
MC38 tumors after anti-VEGFA/Ang2/CD40 treatment. We
observed trends toward increased numbers of perivascular CD8+
T cells in the tumors of mice that received either anti-VEGFA/
Ang2 or anti-VEGFA/Ang2/CD40 antibodies, compared to the
monotherapies (Fig. 5 E and F). Of note is that perivascular
CD8+ T cells were relatively enriched in the tumor core versus
periphery in the triple combination group (SI Appendix, Fig. S4 E
and F). When we further assessed the abundance of CD8+ T cells
in the periphery and core of MC38 tumors, we found that the
combined treatment enhanced the infiltration of CD8+ T cells to
the tumor core, while CD8+ T cells predominantly localized to
the tumor periphery after anti-CD40 monotherapy (Fig. 5G).
Consistent with these findings, we noted an enrichment in nor-
malized blood vessels in the core of tumors, which was de-
pendent on Ang2 blockade (SI Appendix, Fig. S4G). Together,
these findings highlight the critical contribution of anti-VEGFA/
Ang2−induced vascular normalization to improve trafficking of
tumor-reactive CD8+ T cells upon anti-CD40 immunotherapy.
Fig. 3. Myeloid cell skewing by Ang2/VEGFA blockade in combination with agonist CD40 antibodies. (A) Flow cytometry analysis of tumor-infiltrating F4/80+
TAMs (CD11b+Ly6G−Ly6C−F4/80+) in mice bearing MC38 tumors (Left). TAMs were further assessed for expression of the M2 marker CD206/MRC1 (Middle)
and the ratio between M1 (CD11c+) and M2 (CD206+) TAMs (Right). Each data point represents one mouse. (B) Flow cytometry analyses of tumor infiltrating
TAMs (Left) as well as assessment of M2 marker (Middle) and the ratio between M1 and M2 TAMs (Right) was performed as per A in B16-OVA tumor-bearing
mice. Each data point represents one mouse. (C) Flow cytometry analyses of tumor-infiltrating TAMs in mice bearing MMTV-PyMT tumors. Each data point
represents one mouse. (D) Flow cytometry analysis of APCs in B16-OVA tumor-bearing mice. Data represent mean fluorescence intensity (MFI) of CD86 (Left)
or MHC-II (Middle) on CD11chi (F4/80−) APCs and MFI of SIINFEKL peptide in complex with H-2Kb major histocompatibility on CD11chiMHC-IIhi APCs (Right)
after gating on CD11b+Ly6G−Ly6C−F4/80− cells. Each data point represents one mouse. Data indicate mean values ± SEM. Statistical analyses by 1-way ANOVA
with Tukey’s correction for multiple comparisons (black) or pairwise Student’s t test (red), unless otherwise indicated in Dataset S2. The number of mice
employed in each experiment is reported in Dataset S2.
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Fig. 4. Gene expression analysis of tumor-infiltrating immune cells and ECs. (A) Venn diagram of genes differentially expressed (up- and down-regulated
compared to control IgG) according to RNA-seq in CD8+, F4/80+ (MØ), CD4+, and CD31+ cells sorted from orthotopic MMTV-PyMT tumors at day 5 post-
treatment (4 mice per cell type per treatment). (B) Heatmaps of genes differentially and uniquely expressed (from A) after anti-VEGFA/Ang2/CD40 treatment
in CD8+ cells (Left, 164 genes) and macrophages (Right, 368 genes). Expression of these genes is shown across the 4 treatment groups. (C and D) Pathway
analysis scores for gene transcripts in CD31+, CD4+, CD8+, and F4/80+ cells, according to bulk RNA sequencing. (E) The qPCR analysis of Il12, Il1b, Cxcl9, and
Cxcl10 from whole-tumor lysates of MMTV-PyMT mice at day 5 posttreatment. Data indicate the mean fold change over control (IgG treatment) after
normalization to the average of Hprt and Gapdh housekeeping genes. Each data point represents one mouse. Data indicate mean values ± SEM. Statistical
analyses by 1-way ANOVA with Tukey’s correction for multiple comparisons (black) or pairwise Student’s t test (red) unless otherwise indicated in Dataset S2.
The number of mice employed in each experiment is reported in Dataset S2.
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Fig. 5. Intratumoral T cell infiltration and spatial redistribution after Ang2/VEGFA blockade in combination with agonist CD40 antibodies. (A–C) Flow
cytometry analysis of tumor-infiltrating CD8+ T cells in (A) MC38 and (B) B16-OVA tumors, and (C) FoxP3+ Treg cells (Left) and CD8+/Treg ratio (Right) in
MC38 tumors after treatment with the indicated antibodies. Each data point represents one mouse. (D) Flow cytometry analysis of adoptively transferred
OVA-specific CD8+ T cells (CD8+CD45.2+CD45.1−) in tumors, TDLNs, and spleen of CD45.1+C57BL/6 mice treated as indicated. Each data point represents one
mouse. (E and F) Quantification of perivascular CD8+ T cells in MC38 tumors. (E) Data indicate the percentage of CD8+ T cells located in the perivascular space
(5 to 25 μm from the closest CD31+ blood vessel) in 2 to 3 tumors per treatment. (F) Representative images show anti-CD31 (magenta) and anti-CD8 (brown)
immunostaining, and hematoxylin staining (light blue) of tumor sections. (Scale bar, 100 μm.) (G) Intratumoral distribution of CD8+ T cells in MC38 tumors.
Representative images (Upper) from tumor periphery and tumor core are shown after anti-CD8 (brown) immunostaining and hematoxylin staining (light
blue) of tumor sections. (Scale bar, 50 μm.) For each tumor, the number of CD8+ T cells in the tumor periphery and tumor core (>200 μm from tumor margin)
were quantified (Bottom). For each tumor, at least 4 images from each compartment were analyzed and the counts averaged. Each data point represents one
mouse. Data indicate mean values ± SEM. Statistical analyses by 1-way ANOVA with Tukey’s correction for multiple comparisons (black) or pairwise Student’s
t test (red) unless otherwise indicated in Dataset S2. The number of mice employed in each experiment is reported in Dataset S2.
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Anti-VEGFA/Ang2/CD40−Based Immunotherapy Improves the Effector
Functions of Intratumoral T Cells.We next examined the functional
activity of tumor-infiltrating CD8+ T cells. Gene set enrichment
analysis (GSEA) of RNA-seq data indicated that the combina-
tion therapy induced the highest cell cycle activity in MMTV-
PyMT tumor-derived CD8+ T cells, compared to other treat-
ments (Fig. 6A). Similarly, we observed significantly higher pro-
liferation of tumor-specific CD8+ T cells (by anti-Ki67 staining) in
MC38-OVA tumors, but not TDLNs, of anti-VEGFA/Ang2/
CD40−treated mice (Fig. 6 B, Left). These data suggest that anti-
VEGFA/Ang2/CD40 therapy promoted the selective expansion of
tumor-specific T cells in the tumor microenvironment.
We then analyzed perforin expression as a marker of T cell
activation. We scored higher numbers of perforin+ cells in
MC38 tumors after anti-VEGFA/Ang2/CD40 therapy (Fig. 6 C
andD). Furthermore, the combined therapy up-regulated perforin
mRNA in CD8+ T cells isolated from MMTV-PyMT tumors,
compared to the other treatments (Fig. 6E). In addition, the
combined therapy down-regulated the Th2 signatures of CD4+
T cells in these tumors (SI Appendix, Fig. S5), which suggested
preferential skewing of the CD4+ T cells toward Th1 orientation.
Taken together, these data strongly suggest that combined anti-
VEGFA/Ang2/CD40 therapy promoted an antitumoral T cell
phenotype that was conducive to tumor rejection in mice.
Discussion
Although initial phase I studies of agonistic anti-CD40 monotherapy
have demonstrated objective tumor responses in solid tumors (38),
full therapeutic potential of CD40 agonism is likely to be realized in
combination with other, nonredundant immune modulators.
Herein we show that, by synergistic mechanisms with antibodies
cotargeting VEGFA and Ang2, the therapeutic efficacy of ago-
nistic CD40 antibodies in different mouse cancer types is dra-
matically improved. Our approach may be particularly relevant
for tumors with deficient or insufficient T cell priming, a root
cause of immune exclusion (2, 40). CD40 activation is a thera-
peutically tractable approach, which effectively stimulates antitu-
mor immune responses proximal to T cell priming (3). Clinically
relevant factors that establish a T cell-poor tumor and those that
can be antagonized by anti-CD40 treatments include impaired
T cell trafficking into the tumor, as well as hostile factors in the
Fig. 6. Functional characterization of intratumoral CD8+ T cells. (A) GSEA of RNA-seq data for cell cycling-related gene transcripts in cells sorted from
orthotopic MMTV-PyMT tumors at day 5 posttreatment (4 mice per cell type per treatment). Positive and negative scores indicate increased and decreased cell
cycling activity, respectively. (B) Flow cytometry analysis of Ki67 of adoptively transferred CD45.2+ OVA-CD8+ T cells in MC38-OVA tumors (Left) and TDLN
(Right). Each data point represents one mouse. (C and D) Quantification of perforin+ cells in MC38 tumors. (C) Data indicate the number of perforin+ cells per
unit of area. Each data point represents one tumor, of which at least 6 images were analyzed. (D) Representative images show antiperforin (brown)
immunostaining and hematoxylin/eosin staining (light blue) of tumor sections. (Scale bar, 50 μm.) (E) RNA sequencing of Prf1 gene expression in CD8+ T cells
sorted from orthotopic MMTV-PyMT tumors at day 5 posttreatment (4 mice per treatment). Data are shown as log2-transformed RPKM (reads per kilobase
per million mapped reads). Each data point represents one mouse. Data indicate mean values ± SEM. Statistical analyses by 1-way ANOVA with Tukey’s
correction for multiple comparisons (black) or pairwise Student’s t test (red) unless otherwise indicated in Dataset S2. The number of mice employed in each
experiment is reported in Dataset S2.
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tumor microenvironment that limit intratumoral T cell persistence
(40). Importantly, additional key factors that control immune ex-
clusion in the tumor are dysfunctional blood vessels mediated
through aberrant angiogenesis (7). We therefore hypothesized
that CD40 activation in combination with antiangiogenic VEGFA/
Ang2 blockade could ultimately trigger T cell immunity and rep-
resent a clinically relevant opportunity for cancers lacking effector
immune populations.
Mechanistically, we observed improved perfusion and reduced
leakiness of the remaining tumor vasculature in anti-VEGFA/
Ang2−treated tumors, a phenotype that was associated with in-
creased perivascular accumulation and intratumoral infiltration of
CD8+ T cells. Notably, these effects on the spatial redistribution of
effector T cells were independent of CD40 engagement, but es-
sentially driven by Ang2 blockade. Stabilization or maturation of
tumor microvessels was shown previously to facilitate T cell ex-
travasation (10, 11, 22, 26, 27) and to alleviate tumor hypoxia,
which improves lymphocyte function (10, 11). Various anti-
angiogenic agents, including bevacizumab (an anti-human VEGFA
antibody), sunitinib, and axitinib (2 tyrosine kinase inhibitors that
potently block tumor angiogenesis), increased tumor infiltration by
both CD4+ and CD8+ T cells (41, 42). When combined with an
agonistic anti-CD137 antibody, which activates T cells, axitinib
facilitated tumor regression (42). In our study, we observed a
substantial increase in the CD8+/Treg cell ratio and ablated
immunosuppressive Th2 CD4+ T cell signatures in tumors
exposed to combinations of anti-CD40 and anti-VEGFA/
Ang2 antibodies. Although anti-CD40 monotherapy increased
CD8+ T cell numbers per se, in line with previous studies (31,
43), only its combination with antiangiogenic antibodies pro-
moted homing of tumor antigen-specific T cells and intratumoral
infiltration of CD8+ T cells. This may be a consequence of vas-
cular normalization, chemokine secretion from the tumor micro-
environment, and enhanced T cell migration to the otherwise
refractory tumor microenvironment (10, 11). Improved T cell
extravasation was observed previously also in human melanoma
after combined bevacizumab and ipilimumab, an anti-CTLA4
antibody (44).
VEGFA/Ang2 blockade also triggered the polarization of
TAMs to proinflammatory M1-like TAMs (45–47). The dual
targeting of VEGFA and Ang2 was shown previously to increase
M2 to M1-like skewing, which is indicative of a proinflammatory
macrophage activation (22, 24, 25). In other studies, durable
antitumor responses observed upon combining CD40 agonism
with anti-CSF1R antibodies (36) or small-molecule CSF1R in-
hibitors (37, 48) were attributed to the reduction of immuno-
suppressive M2-like TAMs and the simultaneous induction of
polyfunctional inflammatory M1-like TAMs producing TNFα,
IL-6, and IL-12. In our study, we observed a more pronounced
effect on TAM depletion after anti-CD40 therapy in MC38 tu-
mors compared to others (36). Increased frequency of dosing
and earlier time of assessment may explain such differences.
Our transcriptome analysis of TAMs supports the notion that
antibody-mediated CD40 activation, particularly when combined
with dual VEGFA/Ang2 blockade, generates a proinflammatory
tumor microenvironment characterized by enhanced production
of inflammatory cytokines (IL-1β, IL12, IL6, and IFNg) and
T cell-recruiting chemokines (CXCL9 and CXCL10). This may
be a consequence of the enhanced M1-like polarization of TAMs
observed after combination therapy. Furthermore, the induction
of NFkB activity and its upstream regulators TLR4 and
MyD88 in TAMs may contribute to the increase of TNFα and
other proinflammatory cytokines (49). TAM depletion would be
required to assess whether in situ activated TAMs are a key ef-
fector cell population in our studies.
The addition of CD40 to dual VEGFA/Ang2 blockade further
induced the maturation and/or activation of DCs. In mouse tu-
mor models, response to agonistic CD40 therapy was shown to
be dependent on the presence of CD40-activated APCs (35),
which correlated with improved activation of endogenous tumor-
specific T cells (5). Blocking VEGFA and Ang2 enhances the
antigen-presenting capacity of DCs in mouse tumor models (22,
50), while CD40 activation boosts adaptive immune responses
through T cell priming (3). In B16-OVA tumors, the combined
therapy promoted DCs to exhibit an activated phenotype char-
acterized by enhanced expression of MHC-II and CD86 and
cross-presentation of the surrogate OVA tumor antigen. Overall,
T cell priming by APC activation, M1-like TAM polarization,
and proinflammatory cytokine increase, in addition to vascular
normalization, can contribute to sustaining the infiltration and
function of tumor-reactive T cells.
The combination of agonistic CD40 antibodies and VEGFA/
Ang2 blockade not only improved tumor infiltration by CD8+
T cells but also enhanced their effector phenotype, namely, by
increasing the proportion of proliferating, perforin-positive cells.
Perforin expression may be enhanced by increased IL-12 produced
in the tumor microenvironment. Indeed, both IL-12 and IL-2 di-
rectly induce perforin expression in T and NK cells, and target cell
killing by CD8+ T cells occurs predominantly through a perforin/
granzyme-dependent degranulation mechanism (51, 52).
In summary, we report that CD40 activation in combination with
dual VEGFA/Ang2 blockade improves CD8+ T cell infiltration
and enables tumor eradication by instigating nonredundant but
synergistic immune and vascular-modulatory mechanisms. This
evidence is supported by our finding that combined anti-VEGFA/
Ang2/CD40 induces a unique and cell type-specific transcriptomic
profile, compared to monotherapies. Our results are in line with
previous studies (22, 24, 31, 36, 53), which indicated that anti-
VEGFA/Ang2 and anti-CD40 monotherapies had limited thera-
peutic activity. Conversely, we observed tumor rejection by com-
bining agonistic CD40 antibodies with Ang2 blockade, a result that
was further improved by concomitant blockade of VEGFA. A
strength of our study is that we obtained largely similar results in
different tumor models and using distinct antibodies targeting
CD40 and VEGFA/Ang2 (see Dataset S1 for details). We consider
our findings useful in the light of current early-phase clinical
studies that investigate agonistic anti-CD40 antibodies in combi-
nation with various antiangiogenic agents.
Materials and Methods
Cell Lines and Culture. Murine MC38 and MC38-OVA colon cancer cells
(provided by Mark Smyth, Peter MacCallum Cancer Centre, Melbourne,
Australia) were cultured in Dulbecco’s modified Eagle’s medium (Gibco)
supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco),
sodium pyruvate (Sigma), penicillin/streptomycin (Gibco), 2 mM L-glutamine
(Sigma), and minimal essential medium nonessential amino acids (Sigma).
B16-OVA cells (provided by Karine Breckpot, Vrije Universiteit Brussel,
Brussels, Belgium) were cultured in Iscove’s modified Dulbecco’s medium
(IMDM; Sigma) supplemented with 10% FBS (Gibco), 2 mM L-glutamine
(Amimed), and a combination of 50 units per mL penicillin and 50 μg/mL
streptomycin (Gibco). The cell lines used in this study were not found in the
database of commonly misidentified cell lines that is maintained by the In-
ternational Cell Line Authentication Committee and the National Center for
Biotechnology Information. The cell lines have not been authenticated re-
cently, but their growth behavior in vitro and in vivo was compatible with
their identity. All cell lines regularly tested negative for Mycoplasma
contamination.
Mice. FVB/n, BALB/c, and C57BL/6 mice were obtained from Charles River
(France or Germany) or Janvier Labs (France) or bred in the animal facility of
the University of Basel. OT-I, C57BL/6-Ly5.1, and FVB/n/MMTV-PyMT (22) mice
were maintained and bred in house at University of Basel or EPFL (Swit-
zerland). All mice were housed under specific pathogen-free conditions and
in accordance with German and Swiss federal regulations.
Mouse Tumor Models. All experiments involving mice were performed
according to protocols approved by the Swiss Canatonal veterinary offices of
Basel-Stadt, Zurich, and Vaud (protocols 2577, 2577.a, 3049, and 3049.a to
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M.D.P. and 2370, 2408, and 2589 to A.Z.). MC38 and B16-OVA tumors were
generated by subcutaneous (s.c.) injection of 0.5 × 106 or 1 × 106 cells, re-
spectively, in 6-to 14-wk-old C57BL/6 mice. E0771 tumor cells (2.5 × 105) were
implanted orthotopically into the mammary fat pad of 6-wk-old female
C57BL/6 mice. CT26 tumor cells (1 × 106) were implanted s.c. into the skin of
6-wk-old BALB/c mice. MMTV-PyMT primary tumor-derived cells (2 × 106)
were implanted orthotopically into the mammary fat pad of 8- to 10-wk-old
female FVB/n mice, as described previously (22). Tumors were grown for
several weeks, according to either a survival schedule (endpoint defined by
tumor volume) or a fixed time point (Dataset S1). Tumor size was measured
by calipers, and the volume was calculated according to the formula
(D*d*d)/2, with D and d being the longest and shortest tumor diameter,
respectively, in millimeters. The mice were scheduled for killing according to
veterinary regulations when the tumors reached a maximum size of
1,500 mm3. All surviving mice reflecting the tail of the curve remained
tumor-free until completion of the experiments and killing.
Therapeutic Trials in Mouse Tumor Models. All antibodies were suspended in
phosphate-buffered saline (PBS) and injected intraperitoneally (i.p.) after
successful establishment of the tumors (at least 50 to 120 mm3). Briefly,
C57BL/6 mice with MC38 tumors (treatment start at 80 to 120 mm3) received
2 doses of anti-VEGFA (B20.4.1, 10 mg/kg) and anti-Ang2 (LC06, 10 mg/kg),
whereas anti-CD40 (1C10, 5 mg/kg) was administered 4 times. C57BL/6 mice
with B16-OVA tumors (treatment start at 80 to 120 mm3) received bispecific
anti-VEGFA/Ang2 antibody (A2V; 20 mg/kg) twice weekly and anti-CD40
(FGK45; 4 mg/kg) once after the first A2V injection. FVB/n mice with
orthotopic MMTV-PyMT tumors (treatment start at about 300 mm3) were
treated weekly with the bispecific anti-VEGFA/Ang2 antibody (A2V; 10 to
20 mg/kg), whereas anti-CD40 (FGK45; 4 mg/kg) was administered once or
3 times, depending on the experiment. C57BL/6 mice with orthotopic
E0771 tumors (treatment start at 80 to 120 mm3) were treated with anti-
VEGFA/Ang2 antibody (A2V; 10 mg/kg) weekly for up to 8 wk, whereas anti-
CD40 (FGK45; 4 mg/kg) was administered once at treatment start. BALB/c
mice with CT26 tumors (treatment start at 80 to 120 mm3) received anti-
VEGFA/Ang2 antibody (A2V; 10 mg/kg) twice weekly for up to 8 wk, whereas
anti-CD40 (FGK45; 4 mg/kg) was administered once at treatment start. Ad-
ditional information is provided in Dataset S1.
Preparation of Tumors, Spleen, and Lymph Nodes for Flow Cytometry. Tumors
were harvested from treated tumor-bearing mice on day 28 or 30 (for
MC38 model) and day 10 or 12 (for B16-OVA model) posttumor cell injection
or at study endpoint when tumors reached 1,000 mm3 (for MMTV-PyMT
model), as indicated in Dataset S1. MC38 tumors were minced using razor
blades followed by digestion with accutase (PAA), collagenase IV (Worthington),
hyaluronidase (Sigma), and DNase type IV (Sigma) for 60 min at 37 °C with
constant shaking. B16-OVA and PyMT tumors were digested with colla-
genase IV (0.2 mg/mL; Worthington), dispase (2 mg/mL; Life Technolo-
gies), and DNase I (0.1 mg/mL; Life Technologies) in IMDM medium
(without any supplements) for 30 min at 37 °C. The cell suspensions were
filtered using a cell strainer (70 μm). Spleen and LN-derived cells were
isolated by mashing using the end of a 1-mL syringe. Cells were filtered
through a 70-μm nylon mesh. Red blood cells (RBCs) were lysed using RBC
lysis buffer (eBioscience). Single-cell suspensions derived from tumor,
spleen, and LN were blocked with rat anti-mouse FcγIII/II receptor (CD16/
CD32) blocking antibodies (“Fc-Block”) and stained with live/dead cell-
exclusion dye (Zombie UV dye; Biolegend). The cells were then incu-
bated with fluorophore-conjugated antibodies directed against cell sur-
face antigens, washed, and resuspended in fluorescence-activated cell
sorter (FACS) buffer (PBS + 2% FBS). For intracellular antigens (FoxP3 and
Ki67), cells stained with cell surface antibodies were fixed (IC fix; eBioscience)
and permeabilized (Perm buffer; eBioscience) prior to incubation with anti-
bodies directed at intracellular antigens. Cell populations were analyzed on BD
Fortessa. Flow cytometry analysis of cell populations were performed on
BD Fortessa (as per SI Appendix).
Adoptive Transfer of OT-I Cells in MC38-OVA Tumor-Bearing Mice. OVA-specific
CD8+ T cells were obtained from spleen and inguinal and axial lymph nodes
of OT-I TCR transgenic C57BL/6 mice (Ly5.2). The CD8+ T cell negative se-
lection kit (Stemcell Technologies) was used to isolate a pure population of
CD8+ T cells (98% CD8+ T cells as determined by FACS). OT-I T cells were then
cultured in 10-cm plates prebound with anti-CD3 and anti-CD28 antibodies
(10 μg/mL each) for 72 h in Roswell Park Memorial Institute (RPMI) medium
+10% FBS. On day 22 posttumor cell injection, 2 × 106 OT-I cells were in-
jected i.v. into MC38-OVA−bearing C57BL/6 (Ly5.1) mice. Eight days post–
OT-I adoptive transfer (day 30 posttumor cell injection), mice were killed,
and tumor and TDLNs (right inguinal and axial lymph nodes) were collected
for assessment by flow cytometry (as per SI Appendix).
In Vivo Labeling of Functional Tumor Blood Vessels for Assessment of Leakiness
and Perfusion. Blood vessel leakiness and perfusion was assessed on day-28
MC38 tumors in terminally anesthetized mice. Leaky blood vessels were
detected by i.v. injecting 250 μg of fluorescein-labeled dextran (70 kDa,
D-1822; Life Technologies) in 200 μL of PBS. After a circulation time of 5 min,
the mice were first perfused via the left cardiac ventricle with PBS and
subsequently with 4% paraformaldehyde (PFA). For the detection of per-
fused blood vessels, 100 μg of fluorescein-labeled lycopersicon esculentum
(tomato) lectin (GL-1171; Vector Laboratories) was injected in 100 μL of PBS
i.v. via the tail vein. After a circulation time of 4 min, the mice were perfused
with 4% PFA followed by PBS via the left cardiac ventricle. Tumors were
frozen and embedded in Tissue-Tek optimal cutting temperature compound
using standard protocols, and stored at −80 °C. The tissues were cut into
8-μm-thick sections using a cryotome and dried for 30 min at room tempera-
ture protected from light. Subsequently, tissue sections were rehydrated in PBS
for 5 min, permeabilized in PBS/0.1% Triton X-100 for 20 min, and blocked
with PBS/5% normal goat serum (ngs; Sigma). The rat anti-CD31 antibody
(550274; BD Pharmingen) was diluted 1:50 in PBS/5% ngs and used for in-
cubating the slides overnight in a humid chamber at 4 °C. The slides were
subsequently washed 3 times for 5 min in PBS and incubated with the sec-
ondary anti-rat Alexa 568 antibody (molecular probes; 1:200 in PBS/5% ngs).
After a washing step of 3 times 5 min, nuclei were stained with DAPI (1:10,000
Sigma), and slides were mounted with Dako mounting medium (Dako) and
stored in the dark (4 °C) until analysis.
Immunostaining. Formalin-fixed paraffin-embedded tumors or fresh frozen
tumors were prepared for immunostaining of CD8+ T cells, CD31+, and/or NG2+
tumor blood vessels as per SI Appendix. The immunostained tumors were then
analyzed using ImageJ for assessment of tumor necrosis, percentage of
pericyte-covered blood vessels, and perivascular CD8+ T cells as per SI Appendix.
Sorting of MMTV-PyMT Tumor-Derived Cells for RNA-seq. Orthotopic MMTV-
PyMT tumors were generated as described above, and cells were sorted
and analyzed as described previously (22). When tumors reached a size of
about 300 mm3, mice were injected i.p. with the antibodies indicated in
Dataset S1. Five days later, mice were killed, and tumors were harvested and
prepared for flow cytometry staining as described above. Cells were stained
for CD45, CD8, CD4, CD31, CD11b, F480, and 7-AAD. After live/dead and
single-cell discrimination, cell populations were discriminated according to
the following markers: ECs: CD45−CD31+; TAMs: CD45+CD11b+F480+; CD8+
T cells: CD45+CD11b−CD8+; CD4+ T cells: CD45+CD11b−CD4+. Cell sorting was
performed using FACS Aria II (BD). Each cell population (n = 4) was isolated
from an independent tumor. Typically, 2 × 104 to 2 × 105 cells were obtained
for each cell population.
RNA-seq and Computational Signature Analysis. RNA-seq of sorted cell pop-
ulations was performed and analyzed as recently described by us (22, 47). The
gene expression cutoffs to classify up and down-regulated genes compared to
control IgG were set as follows: raw P values less than 0.05 and absolute
log2 ratio greater than 1. Data are deposited in NCBI Gene Expression Om-
nibus (GEO) under GSE94920. GSEA-like signature analysis on transcriptome-
wide gene expression values was performed using the function signedRankSumTest
from the gCMAP package (54). This analysis generated Wilcoxon/Mann−
Whitney rank sum statistics representing the activation level or likelihood
level of the pathway or phenotype characterized by a signature in a treat-
ment group compared to another, with an associated P value to denote the
statistical significance. Signatures were obtained from Molecular Signatures
Database (55). Pathway analysis for only genes that passed criteria of raw P
value less than 0.05 and absolute log2 fold change of more than 1 was
performed using Ingenuity Pathway Analysis software.
Statistical Analysis. Detailed statistical analyses are described in SI Appendix.
Statistical significance is indicated in the figures as follows: *0.01 ≤ P < 0.05;
**0.001 ≤ P < 0.01; ***P < 0.001. P values > 0.05 are not indicated. “N”
values are indicated in Dataset S2. On rare occasions, outliers at the end-
point were excluded by using the ROUT (robust regression followed by
outlier identification) method (provided in GraphPad Prism) to identify
outliers. In some cases, selected samples were excluded from specific anal-
yses because of technical flaws during sample processing or data acquisition.
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Data and Materials Availability. Primary RNA-seq data sets have beendeposited
in the Gene Expression Omnibus (GEO), https://www.ncbi.nlm.nih.gov/geo/
under accession code GSE94920. A2V, LC06, B20, and isotype-matched control
IgGs were provided by Roche under conditions expressed in sponsored re-
search agreements between Roche and the corresponding authors’ institutions
(University of Basel and EPFL). Interested researchers may contact Roche for
requests concerning the aforementioned materials.
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